Scholarlink

Background <p><i>Enterobacter hormaechei</i> (<i>E. hormaechei</i>) is an opportunistic pathogen in poultry, increasingly associated with multidrug resistance due to the extensive use of antibiotics in animal production. The emergence of resistant <i>E. hormaechei</i> strains poses a significant threat to poultry health and food safety, highlighting the urgent need for alternative antimicrobial strategies. This study aimed to isolate and characterize a novel lytic bacteriophage targeting <i>E. hormaechei</i> and to evaluate its biological properties and therapeutic potential in a gastrointestinal infection mice model.</p> Results <p>A lytic phage, designated S18-3, was isolated from environmental water using <i>E. hormaechei</i> strain HZW1 isolated from diseased broiler liver. Phage S18-3 forms clear plaques (~ 0.6&#xa0;cm) and exhibits an icosahedral head with a long tail. Optimal infectivity occurs at an MOI of 0.1. S18-3 remains stable from 30 to 50&#xa0;°C and tolerates a broad pH range (pH 4–11). Whole-genome sequencing revealed no known virulence factors or antimicrobial resistance genes, indicating favorable genetic safety. In a murine intestinal infection model established by antibiotic pretreatment and oral challenge, <i>E. hormaechei</i> caused significant weight loss and mortality. Oral administration of S18-3 markedly improved survival and mitigated weight loss compared with infected controls. Phage S18-3 titers were detectable in feces in infection group, with only transient, low-level presence in blood. Histopathology showed no evident liver injury or inflammatory changes, suggesting no hepatotoxicity associated with phage treatment.</p> Conclusions <p>Phage S18-3 is a stable, genetically safe lytic phage that effectively alleviates intestinal <i>E. hormaechei</i> infection in a murine model without observable adverse effects. These data support the potential of S18-3 as an antibiotic alternative for controlling <i>E. hormaechei</i> infections in poultry. Further validation in broiler models and farm-level settings is warranted to assess translational applicability in sustainable poultry production.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Characterization and therapeutic evaluation of a novel phage S18-3 targeting poultry-derived Enterobacter hormaechei infection in mice

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月15日

查看全文
  • Rui Wang,
  • Meiping Zhan,
  • Quan Wang,
  • Ningze Xia,
  • Tianhao Chen,
  • Shuang Gong,
  • Qiong Zhang,
  • Ling Liu,
  • Yibo Zhang,
  • Ruixia Zeng

摘要

Background

Enterobacter hormaechei (E. hormaechei) is an opportunistic pathogen in poultry, increasingly associated with multidrug resistance due to the extensive use of antibiotics in animal production. The emergence of resistant E. hormaechei strains poses a significant threat to poultry health and food safety, highlighting the urgent need for alternative antimicrobial strategies. This study aimed to isolate and characterize a novel lytic bacteriophage targeting E. hormaechei and to evaluate its biological properties and therapeutic potential in a gastrointestinal infection mice model.

Results

A lytic phage, designated S18-3, was isolated from environmental water using E. hormaechei strain HZW1 isolated from diseased broiler liver. Phage S18-3 forms clear plaques (~ 0.6 cm) and exhibits an icosahedral head with a long tail. Optimal infectivity occurs at an MOI of 0.1. S18-3 remains stable from 30 to 50 °C and tolerates a broad pH range (pH 4–11). Whole-genome sequencing revealed no known virulence factors or antimicrobial resistance genes, indicating favorable genetic safety. In a murine intestinal infection model established by antibiotic pretreatment and oral challenge, E. hormaechei caused significant weight loss and mortality. Oral administration of S18-3 markedly improved survival and mitigated weight loss compared with infected controls. Phage S18-3 titers were detectable in feces in infection group, with only transient, low-level presence in blood. Histopathology showed no evident liver injury or inflammatory changes, suggesting no hepatotoxicity associated with phage treatment.

Conclusions

Phage S18-3 is a stable, genetically safe lytic phage that effectively alleviates intestinal E. hormaechei infection in a murine model without observable adverse effects. These data support the potential of S18-3 as an antibiotic alternative for controlling E. hormaechei infections in poultry. Further validation in broiler models and farm-level settings is warranted to assess translational applicability in sustainable poultry production.